Fall Clinical Dermatology Conference — Publications

Fall Clinical Dermatology Conference

Publications

Northwestern University University of Minnesota Mount Sinai

Race and ethnicity sub-groups of alopecia areata patients have differing clinical characteristics: TARGET-DERM AA

AbbVie Inc.Mount Sinai

Generic vs. disease-specific patient reported outcome (PRO) instruments for assessing HRQoL burden among patients diagnosed with alopecia areata: Evidence from TARGET-DERM AA

Medical University of South Carolina Northwestern University University of Minnesota Mount Sinai

Demographics and disease characteristics of patients with alopecia areata with comorbid atopic dermatitis, vitiligo or anxiety/depression: TARGET-DERM AA

George Washington University Yale University

Why Do Optimal Targets for Itch and Skin Clearance Matter in Atopic Dermatitis Treatment? Insights from the TARGET-DERM AD Registry

AbbVie Inc.Rady Children's Hospital UCSD George Washington University

Persistent Inadequate Disease Control and Therapeutic Inertia in Moderate-to-Severe Atopic Dermatitis: A 12-month Longitudinal Analysis of Real-world Outcomes from the TARGET-DERM AD registry (Fall Clinical 2024)

5

Total Publications

5

Poster Presentation

2025 · Poster Presentation · Northwestern University · Dermatology

Race and ethnicity sub-groups of alopecia areata patients have differing clinical characteristics: TARGET-DERM AA

2025 · Poster Presentation · AbbVie Inc. · Dermatology

Generic vs. disease-specific patient reported outcome (PRO) instruments for assessing HRQoL burden among patients diagnosed with alopecia areata: Evidence from TARGET-DERM AA

2024 · Poster Presentation · Medical University of South Carolina · Dermatology

Demographics and disease characteristics of patients with alopecia areata with comorbid atopic dermatitis, vitiligo or anxiety/depression: TARGET-DERM AA

2024 · Poster Presentation · George Washington University · Dermatology

Why Do Optimal Targets for Itch and Skin Clearance Matter in Atopic Dermatitis Treatment? Insights from the TARGET-DERM AD Registry

2024 · Poster Presentation · AbbVie Inc. · Dermatology

Persistent Inadequate Disease Control and Therapeutic Inertia in Moderate-to-Severe Atopic Dermatitis: A 12-month Longitudinal Analysis of Real-world Outcomes from the TARGET-DERM AD registry (Fall Clinical 2024)